7 results on '"Wang, TongShan"'
Search Results
2. Pamiparib dose escalation in Chinese patients with non‐mucinous high‐grade ovarian cancer or advanced triple‐negative breast cancer.
- Author
-
Xu, Binghe, Yin, Yongmei, Dong, Mei, Song, Yan, Li, Wei, Huang, Xiang, Wang, Tongshan, He, Jing, Mu, Xiyan, Li, Li, Mu, Song, Zhang, Wa, and Li, Miao
- Subjects
- *
TRIPLE-negative breast cancer , *OVARIAN cancer , *CHINESE people , *MUCINOUS adenocarcinoma , *HEREDITARY cancer syndromes - Abstract
Background: The recommended phase 2 dose (RP2D) of pamiparib, an investigational PARP1/2 inhibitor, was established as 60 mg twice daily (BID) in a first‐in‐human (FIH) study (NCT02361723). Methods: Chinese patients with advanced non‐mucinous high‐grade ovarian cancer (HGOC) or triple‐negative breast cancer (TNBC) whose disease either progressed despite standard therapy, or for which there is no standard therapy were enrolled in the dose‐escalation (DE) portion of a phase 1/2 study (NCT03333915). The primary endpoint was safety/tolerability; secondary objectives were pharmacokinetics and antitumor activity. BRCA1/2 mutation status was retrospectively evaluated. Results: Nine HGOC and six TNBC patients (N = 15; n = 4, 20 mg; n = 4, 40 mg; n = 7, 60 mg) were enrolled; as of 30 September 2019, one HGOC patient remained on treatment. Seven patients (n = 5, HGOC; n = 2, TNBC) had germline BRCA1/2 mutation (gBRCAmut); all HGOC patients were resistant/refractory to platinum. Asthenia and nausea (n = 12 each) were the most common treatment‐related adverse events (TRAEs). Decreased hemoglobin was the most common grade 3 TRAE (n = 3); no grade ≥4 AEs were observed. No dose‐limiting toxicities (DLTs) were reported. Pamiparib plasma exposure was similar to exposure observed in the FIH study after a single‐dose administration, albeit slightly higher at steady state. Among 13 RECIST‐evaluable patients, two with HGOC (gBRCAmut, n = 1) achieved a confirmed partial response and six with HGOC (gBRCAmut, n = 4) achieved stable disease; all TNBC RECIST‐evaluable patients (n = 5) reported progressive disease. Conclusions: Pamiparib was generally well tolerated in Chinese patients, with durable responses observed in patients with HGOC. Based on these results, pamiparib 60 mg BID was confirmed as the RP2D. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Identification of a 7‐microRNA signature in plasma as promising biomarker for nasopharyngeal carcinoma detection.
- Author
-
Zhang, Huo, Zou, Xuan, Wu, Lirong, Zhang, Shiyu, Wang, Tongshan, Liu, Ping, Zhu, Wei, and Zhu, Jun
- Subjects
- *
REVERSE transcriptase polymerase chain reaction , *RECEIVER operating characteristic curves - Abstract
Background: Circulating microRNAs (miRNAs) have become reliable sources of non‐invasive biomarkers for cancer diagnosis. Identification of promising miRNA biomarkers in plasma might benefit a lot to the detection of nasopharyngeal carcinoma (NPC). Methods: The Exiqon miRNA qPCR panel was used in the screening stage to identify candidate miRNAs, which were further verified by quantitative reverse transcription polymerase chain reaction (qRT‐PCR) in the following three stages among plasma samples from 200 NPC patients and 189 healthy donors (as normal controls [NCs]). The identified miRNAs were further explored in tissue specimens (48 NPC vs 32 NCs) and plasma exosomes (32 NPC vs 32 NCs). Survival analyses were ultimately conducted by Cox regression models and Kaplan‐Meier curves using log‐rank tests. Results: We identified a 7‐miRNA signature including let‐7b‐5p, miR‐140‐3p, miR‐144‐3p, miR‐17‐5p, miR‐20a‐5p, miR‐20b‐5p, and miR‐205‐5p in plasma for NPC diagnosis after four‐stage validation. The areas under the receiver operating characteristic curve (AUCs) for the signature were 0.879, 0.884, 0.921, and 0.807 for the training, testing, external validation stage, and the combined three stages, respectively. In NPC tissues, miR‐144‐3p, miR‐17‐5p, miR‐20a‐5p, and miR‐205‐5p were consistently up‐regulated while let‐7b‐5p and miR‐140‐3p were significantly down‐regulated compared to NCs. However, none of the seven identified miRNAs were dysregulated in plasma‐derived exosomes in NPC patients. As to survival analysis, none of the seven miRNAs seemed to be associated with NPC prognosis. Conclusion: We identified a 7‐miRNA signature in plasma as promising non‐invasive biomarkers for NPC detection. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. A five‐miRNA panel in plasma was identified for breast cancer diagnosis.
- Author
-
Li, Minghui, Zou, Xuan, Xia, Tiansong, Wang, Tongshan, Liu, Ping, Zhou, Xin, Wang, Shui, and Zhu, Wei
- Subjects
- *
CANCER diagnosis , *BREAST cancer - Abstract
Breast cancer (BC) is one of the most common cancers in females. Since early detection can bring prognosis benefit, discovery of novel noninvasive biomarkers for BC diagnosis is in urgent need. In this four‐phase study, we profiled miRNA expression in plasma samples from a total of 257 BC patients and 257 normal controls (NCs). Exiqon miRNA qPCR panel was used to select candidate miRNAs in the screening phase which were further analyzed using qRT‐PCR in the following training, testing and external validation phases. Finally, we identified five plasma miRNAs (let‐7b‐5p, miR‐122‐5p, miR‐146b‐5p, miR‐210‐3p and miR‐215‐5p) whose expression levels were significantly different between BC patients and NCs. A 5‐miRNA panel in plasma with high sensitivity and specificity was then constructed to detect BC. The areas under the receiver‐operating characteristic curves (AUCs) of the panel were 0.683, 0.966, 0.978 for the training, testing and external validation sets, respectively. Expression of the identified miRNAs was further analyzed among 32 pairs of BC tissue and the adjacent normal tissue samples as well as plasma‐derived exosome samples from 32 BC patients vs 32 NCs. Let‐7b‐5p was contrarily down‐regulated in BC tissue. In exosomes samples, only miR‐122‐5p was significantly up‐regulated as in plasma for BC patients. In conclusion, we identified a 5‐miRNA plasma panel (let‐7b‐5p, miR‐122‐5p, miR‐146b‐5p, miR‐210‐3p and miR‐215‐5p) that could serve as a promising biomarker for BC detection. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. Identification of four plasma microRNAs as potential biomarkers in the diagnosis of male lung squamous cell carcinoma patients in China.
- Author
-
Shan, Xia, Zhang, Huo, Zhang, Lan, Zhou, Xin, Wang, Tongshan, Zhang, Jinying, Shu, Yongqian, Zhu, Wei, Wen, Wei, and Liu, Ping
- Subjects
- *
MICRORNA genetics , *BLOOD plasma , *BIOLOGICAL tags , *SQUAMOUS cell carcinoma , *POLYMERASE chain reaction , *PATIENTS - Abstract
Abstract: Dysregulated microRNAs (miRNAs) in the plasma of patients with lung squamous cell carcinoma (LSCC) might serve as biomarkers for LSCC diagnosis. The expression of miRNAs was performed using quantitative reverse transcription–polymerase chain reaction (qRT‐PCR) on the basis of Exiqon panels in the initial screening phase including three male LSCC pool samples and one normal control (NC) pool sample (per 10 samples were pooled as one pool sample). After the training (32 LSCC vs. 31 NCs), the testing (55 LSCC vs. 55 NCs), and the external validation (15 LSCC vs. 15 NCs) stages via qRT‐PCR, a four‐miRNA signature (miR‐181a‐5p, miR‐21‐5p, miR‐106a‐5p, and miR‐93‐5p) was identified for LSCC detection. Areas under the receiver operating characteristic (ROC) curve (AUC) of the four‐miRNA panel for the training, the testing, and the external validation phases were 0.795, 0.827, and 0.914, respectively. Then, the four miRNAs were explored in LSCC tissue samples (23 LSCC vs. 23 NCs), and their expression was significantly up‐regulated. However, none of the four miRNAs found significantly up‐regulated in plasma exosomes expect miR‐93‐5p with borderline significance (16 LSCC vs. 16 NCs). In summary, our study established a four‐miRNA peripheral plasma signature, which contributed to diagnosing male LSCC patients in China to a certain degree. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. Rare earth elements (REEs) geochemistry of Sinian-Cambrian reservoir solid bitumens in Sichuan Basin, SW China: potential application to petroleum exploration.
- Author
-
Gao, Ping, Liu, Guangdi, Wang, Zecheng, Jia, Chengzao, Wang, Tongshan, and Zhang, Pengwei
- Subjects
- *
RARE earth metals , *GEOCHEMISTRY , *RESERVOIRS , *PETROLEUM prospecting - Abstract
In order to evaluate rare earth elements (REEs) as a potential proxy for solid bitumen classification, we employed traditional correlation approaches, such as carbon isotopes and V/(V + Ni) ratios, to infer the source rocks of Sinian-Cambrian reservoir solid bitumens in the Sichuan Basin and analyse solid bitumens for their REE compositions by inductively coupled plasma-mass spectrometry. Our data suggested that Sinian-Cambrian reservoir solid bitumens were primarily sourced from the lower Cambrian shales deposited under anoxic-euxinic conditions. REE and their associated parameters seemed to be more sensitive to classify solid bitumens than traditional correlation approaches. REE concentrations played a dominant role and fractionation degree between light and heavy REE and played a secondary role in solid bitumen classification. REE concentration and pattern in solid bitumens might be controlled by two processes, including inheritance from source rocks and water-rock interaction. The major factor controlling REE concentrations in solid bitumens was the type of organic matter of source rocks. Authigenic minerals in solid bitumens formed by water-rock interaction appeared to have little influence on REE compositions of solid bitumens because of their trace contents. Overall, REE could be used as a novel complementary approach to solid bitumen classification in complicated petroleum systems. Copyright © 2015 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. A novel serum microRNA signature to screen esophageal squamous cell carcinoma.
- Author
-
Huang, Zebo, Zhang, Lan, Zhu, Danxia, Shan, Xia, Zhou, Xin, Qi, Lian‐wen, Wu, Lirong, Zhu, Jun, Cheng, Wenfang, Zhang, Huo, Chen, Yan, Zhu, Wei, Wang, Tongshan, and Liu, Ping
- Subjects
- *
MICRORNA , *DIAGNOSIS of esophageal cancer , *SQUAMOUS cell carcinoma , *BIOMARKERS , *REVERSE transcriptase polymerase chain reaction , *EXOSOMES - Abstract
Circulating microRNAs (miRNAs) have been used as promising diagnostic biomarkers for esophageal squamous cell carcinoma (ESCC). We performed miRNA expression profiling using quantitative reverse transcription polymerase chain reaction (qRT-PCR) based Exiqon panels from three ESCC pools and one normal control (NC) pool samples. Using qRT-PCR, identified serum miRNAs were further confirmed in training (32 ESCC vs. 32 NCs) and testing stages (108 ESCC vs. 96 NCs). Consequently, five serum miRNAs (miR-20b-5p, miR-28-3p, miR-192-5p, miR-223-3p, and miR-296-5p) were significantly overexpressed in ESCC compared with NCs. The diagnostic value of the 5-miRNA signature was validated by an external cohort (60 ESCC vs. 60 NCs). The areas under the receiver operating characteristic curve (ROC) of the 5-miRNA signature were 0.753, 0.763, and 0.966 for the training, testing, and the external validation stages, respectively. The expression levels of the miRNAs were also determined in tissues, arterial serum, and exosomes. MiR-20b-5p, miR-28-3p, and miR-192-5p were significantly upregulated in ESCC tissues, while miR-296-5p was overexpressed in ESCC serum exosomes. In conclusion, we identified a 5-miRNA signature in serum for the detection of ESCC. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.